Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Receivables: 2015-2025

Historic Receivables for Sunshine Biopharma (SBFM) over the last 7 years, with Sep 2025 value amounting to $4.2 million.

  • Sunshine Biopharma's Receivables rose 29.11% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year increase of 19.76%. This contributed to the annual value of $3.9 million for FY2024, which is 51.56% up from last year.
  • Sunshine Biopharma's Receivables amounted to $4.2 million in Q3 2025, which was up 15.83% from $3.6 million recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Receivables peaked at $4.2 million during Q3 2025, and registered a low of $22 during Q3 2022.
  • In the last 3 years, Sunshine Biopharma's Receivables had a median value of $3.2 million in 2024 and averaged $3.0 million.
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 98.05% in 2022, then spiked by 9,245,895.45% in 2023.
  • Quarterly analysis of 5 years shows Sunshine Biopharma's Receivables stood at $7,798 in 2021, then surged by 24,421.07% to $1.9 million in 2022, then spiked by 33.48% to $2.6 million in 2023, then surged by 51.56% to $3.9 million in 2024, then climbed by 29.11% to $4.2 million in 2025.
  • Its Receivables stands at $4.2 million for Q3 2025, versus $3.6 million for Q2 2025 and $3.4 million for Q1 2025.